Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | May 04, 2020 | May 05, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date May 04, 2020 · Filed May 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,860 |
Ending reported balance
After 2020-05-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-05-04 · Exercise / conversion · Acquired 2,416 · Balance 57,276 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Row 2 · 2020-05-04 · Sale · Disposed 2,416 · Balance 54,860 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.63 · Expires 2020-05-11 | Direct | 0 |
Reported balance
After 2020-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-04 · Exercise / conversion · Disposed 2,416 · Balance 0 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The options vested quarterly over the first year of service and were fully vested on May 11, 2011.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2014 Filed May 9, 2014 00:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (Right to Buy) · Derivative | 4,868 | $0.00 Strike: $78.77 | $0.00 |
DisclosureSEC source: 0001179110-14-008016 · edgar.xml · derivative · entry 4 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,868 Underlying: Common Stock · 4,868 shares Expires 2024-05-07 F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 7, 2015, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 07, 2014 Filed May 9, 2014 00:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 1,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-14-008016 · edgar.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,904 Underlying: Common Stock · 1,904 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 7, 2015, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 7, 2015, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2014 Filed May 9, 2014 00:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 2,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-14-008016 · edgar.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,863 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: 100% of the restricted stock units vested on May 6, 2014. F4 · derivative.expiration_date: 100% of the restricted stock units vested on May 6, 2014. Read SEC document |
| May 06, 2014 Filed May 9, 2014 00:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-14-008016 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| April 08, 2014 Filed Apr 10, 2014 18:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001179110-14-006694 · edgar.xml · derivative · entry 4 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,000 Underlying: Common Stock · 5,000 shares Expires 2016-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| April 08, 2014 Filed Apr 10, 2014 18:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,100 | $70.99 | $149,071.02 |
DisclosureSEC source: 0001179110-14-006694 · edgar.xml · nonDerivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,542 F4 · price: Sale prices reported for the transactions reported here range from $70.64 to $71.58. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 08, 2014 Filed Apr 10, 2014 18:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,900 | $70.24 | $203,683.53 |
DisclosureSEC source: 0001179110-14-006694 · edgar.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,642 F3 · price: Sale prices reported for the transactions reported here range from $69.53 to $70.50. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 08, 2014 Filed Apr 10, 2014 18:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $14.34 | $71,687.50 |
DisclosureSEC source: 0001179110-14-006694 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2014 Filed Mar 18, 2014 16:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001179110-14-005350 · edgar.xml · derivative · entry 4 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Stock · 14,000 shares Expires 2016-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| March 14, 2014 Filed Mar 18, 2014 16:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $77.07 | $15,414.00 |
DisclosureSEC source: 0001179110-14-005350 · edgar.xml · nonDerivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,542 Read SEC document |
| March 14, 2014 Filed Mar 18, 2014 16:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 13,800 | $76.43 | $1,054,687.08 |
DisclosureSEC source: 0001179110-14-005350 · edgar.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,742 F3 · price: Sale prices reported for the transactions reported here range from $75.87 to $76.86. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 14, 2014 Filed Mar 18, 2014 16:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 14,000 | $14.34 | $200,725.00 |
DisclosureSEC source: 0001179110-14-005350 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2013 Filed Aug 5, 2013 20:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $10.99 | $0.00 |
DisclosureSEC source: 0001179110-13-012642 · edgar.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires 2015-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| August 02, 2013 Filed Aug 5, 2013 20:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 17,000 | $61.51 | $1,045,637.70 |
DisclosureSEC source: 0001179110-13-012642 · edgar.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,542 F3 · price: Sale prices reported for the transactions reported here range from $61.40 to $61.81. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 02, 2013 Filed Aug 5, 2013 20:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 17,000 | $10.99 | $186,872.50 |
DisclosureSEC source: 0001179110-13-012642 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2013 Filed Jul 3, 2013 21:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $10.99 | $0.00 |
DisclosureSEC source: 0001179110-13-011554 · edgar.xml · derivative · entry 5 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 7,000 shares Expires 2015-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| July 02, 2013 Filed Jul 3, 2013 21:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $10.99 | $0.00 |
DisclosureSEC source: 0001179110-13-011554 · edgar.xml · derivative · entry 4 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 10,000 shares Expires 2015-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F1 · derivative.exercise_date: The options have a two year vesting schedule. 50% vest on the first anniversary of the date of grant. The balance vested on the second anniversary of the date of grant. Read SEC document |
| July 02, 2013 Filed Jul 3, 2013 21:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 17,000 | $51.66 | $878,296.50 |
DisclosureSEC source: 0001179110-13-011554 · edgar.xml · nonDerivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,542 F4 · price: Sale prices reported for the transactions reported here range from $51.65 to $51.79. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 02, 2013 Filed Jul 3, 2013 21:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 7,000 | $10.99 | $76,947.50 |
DisclosureSEC source: 0001179110-13-011554 · edgar.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2013 Filed Jul 3, 2013 21:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $10.99 | $109,925.00 |
DisclosureSEC source: 0001179110-13-011554 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2013 Filed Jun 11, 2013 18:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $10.99 | $0.00 |
DisclosureSEC source: 0001179110-13-010122 · edgar.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 110,000 shares Expires 2015-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F1 · derivative.exercise_date: The options have a two year vesting schedule. 50% vest on the first anniversary of the date of grant. The balance vested on the second anniversary of the date of grant. Read SEC document |
| June 07, 2013 Filed Jun 11, 2013 18:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 110,000 | $52.15 | $5,736,885.00 |
DisclosureSEC source: 0001179110-13-010122 · edgar.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,542 F3 · price: Sale prices reported for the transactions reported here range from $51.81 to $52.065. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 07, 2013 Filed Jun 11, 2013 18:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 110,000 | $10.99 | $1,209,175.00 |
DisclosureSEC source: 0001179110-13-010122 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2013 Filed May 14, 2013 22:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 5,852 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-13-008380 · edgar.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,863 Underlying: Common Stock · 5,852 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 10, 2013, at the end of the first year of service. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 10, 2013, at the end of the first year of service. Read SEC document |
| May 10, 2013 Filed May 14, 2013 22:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,852 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-13-008380 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 08, 2013 Filed May 10, 2013 22:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 2,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-13-008226 · edgar.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,715 Underlying: Common Stock · 2,863 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 8, 2014, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 8, 2014, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 08, 2013 Filed May 10, 2013 22:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 8,442 | $0.00 Strike: $52.38 | $0.00 |
DisclosureSEC source: 0001179110-13-008226 · edgar.xml · derivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,442 Underlying: Common Stock · 8,442 shares Expires 2023-05-08 F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 8, 2014, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2012 Filed May 16, 2012 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 3,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-12-008477 · edgar.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,926 Underlying: Common Stock · 3,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 12, 2012, at the end of the first year of service. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 12, 2012, at the end of the first year of service. Read SEC document |
| May 12, 2012 Filed May 16, 2012 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-12-008477 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 10, 2012 Filed May 15, 2012 00:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 2,926 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-12-008415 · edgar.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,558 Underlying: Common Stock · 2,926 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 10, 2013, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 10, 2013, at the end of the first year of service. Read SEC document |
| May 10, 2012 Filed May 15, 2012 00:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 8,161 | $0.00 Strike: $51.25 | $0.00 |
DisclosureSEC source: 0001179110-12-008415 · edgar.xml · derivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,161 Underlying: Common Stock · 8,161 shares Expires 2022-05-10 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 10, 2013. Read SEC document |
| May 01, 2012 Filed May 3, 2012 22:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionPhantom Stock · Derivative | 5,987 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-007711 · edgar.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,987 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F1 · price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · derivative.exercise_date: The shares of phantom stock were fully vested and, at the election of the reporting person, became payable in common stock upon specified deferral dates. F2 · derivative.expiration_date: The shares of phantom stock were fully vested and, at the election of the reporting person, became payable in common stock upon specified deferral dates. Read SEC document |
| May 01, 2012 Filed May 3, 2012 22:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,987 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-12-007711 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. Read SEC document |
| May 12, 2011 Filed May 14, 2011 00:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 3,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-11-007984 · edgar.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,632 Underlying: Common Stock · 3,632 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 12, 2012, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 12, 2012, at the end of the first year of service. Read SEC document |
| May 12, 2011 Filed May 14, 2011 00:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 10,141 | $0.00 Strike: $41.29 | $0.00 |
DisclosureSEC source: 0001179110-11-007984 · edgar.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,141 Underlying: Common Stock · 10,141 shares Expires 2021-05-11 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 12, 2012. Read SEC document |
| May 11, 2011 Filed May 14, 2011 00:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 3,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-11-007984 · edgar.xml · derivative · entry 4 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: 100% of the restricted stock units vested on May 11, 2011, at the end of the first year of service. F4 · derivative.expiration_date: 100% of the restricted stock units vested on May 11, 2011, at the end of the first year of service. Read SEC document |
| May 11, 2011 Filed May 14, 2011 00:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-11-007984 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 11, 2010 Filed May 13, 2010 23:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 3,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-008593 · edgar.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,820 Underlying: Common Stock · 3,820 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 11, 2011, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 11, 2011, at the end of the first year of service. Read SEC document |
| May 11, 2010 Filed May 13, 2010 23:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 10,860 | $0.00 Strike: $39.26 | $0.00 |
DisclosureSEC source: 0001179110-10-008593 · edgar.xml · derivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,860 Underlying: Common Stock · 10,860 shares Expires 2020-05-11 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 11, 2011. Read SEC document |
| May 06, 2010 Filed May 10, 2010 22:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 3,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-008272 · edgar.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,406 F1 · shares: Issuance of common stock upon vesting of certain restricted share units on May 6, 2010. Read SEC document |
| May 06, 2009 Filed May 8, 2009 23:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 3,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-09-007483 · edgar.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,406 Underlying: Common Stock · 3,406 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 6, 2010, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 6, 2010, at the end of the first year of service. Read SEC document |
| May 06, 2009 Filed May 8, 2009 23:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 9,534 | $0.00 Strike: $44.03 | $0.00 |
DisclosureSEC source: 0001179110-09-007483 · edgar.xml · derivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,534 Underlying: Common Stock · 9,534 shares Expires 2019-05-06 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 6, 2010. Read SEC document |
| May 08, 2008 Filed May 9, 2008 23:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (right to buy) · Derivative | 26,250 | $0.00 Strike: $53.23 | $0.00 |
DisclosureSEC source: 0001179110-08-009315 · edgar.xml · derivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2018-05-08 F1 · derivative.exercise_date: Options vest quarterly over a period of one year from date of grant. Read SEC document |
| June 28, 2007 Filed Jul 2, 2007 19:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Shares · Derivative | 1,515.53 | $0.00 Strike: $39.59 | $0.00 |
DisclosureSEC source: 0001179110-07-014128 · edgar.xml · derivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,515.53 Underlying: Common Stock · 1,515.53 shares Expires not disclosed F1 · derivative.exercise_price: All shares and dollar amounts reflect a two-for-one split that was effected on June 22, 2007 benefiting all shareholders of record as of May 24, 2007. F2 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock when the reporting person reaches the age of 65. F2 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock when the reporting person reaches the age of 65. Read SEC document |
| May 09, 2007 Filed May 11, 2007 23:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,250 | $0.00 Strike: $82.82 | $0.00 |
DisclosureSEC source: 0001179110-07-009856 · edgar.xml · derivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2017-05-09 F1 · derivative.exercise_date: Options vested in full on May 9, 2007, the date of grant. Read SEC document |
| July 03, 2006 Filed Jul 6, 2006 18:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 1,012.49 | $59.26 Strike: $59.26 | $60,000.16 |
DisclosureSEC source: 0001179110-06-014740 · edgar.xml · derivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012.49 Underlying: Common Stock · 1,012.49 shares Expires not disclosed F1 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock when the reporting person reaches the age of 65. F1 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock when the reporting person reaches the age of 65. Read SEC document |
| May 10, 2006 Filed May 12, 2006 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,250 | $0.00 Strike: $57.35 | $0.00 |
DisclosureSEC source: 0001179110-06-010650 · edgar.xml · derivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2016-05-10 F1 · kind: Options are granted as part of the annual compensation to non-employee members of the Board of Directors and are immediately exercisable on date of grant. Read SEC document |
| January 26, 2006 Filed Jan 28, 2006 00:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $57.36 | $0.00 |
DisclosureSEC source: 0001179110-06-002223 · edgar.xml · derivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2016-01-26 F1 · derivative.exercise_date: Options are 100% vested on date of grant. Read SEC document |
| July 27, 2005 Filed Jul 29, 2005 23:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock · Derivative | 6,000 | $0.00 Strike: $43.97 | $0.00 |
DisclosureSEC source: 0001179110-05-015030 · edgar.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2015-07-27 Read SEC document |
| July 27, 2005 Filed Jul 29, 2005 23:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $43.97 | $0.00 |
DisclosureSEC source: 0001179110-05-015030 · edgar.xml · derivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2015-07-27 F1 · derivative.exercise_date: Options have a two year vesting schedule, 50% each vesting on the first anniversary and second anniversary of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.